Skip to content
value.today

Tenon Medical, Inc.

TNON
$6 Mmarket cap on Oct 29, 2026+51.5% since Jan 2024
Compare
World rank
#26,612
Revenue
$4 M
For year ending December-2025
Net income
$-13 M
-318.8% margin
SEC filing
Employees
—

Tenon Medical, Inc. in brief

Tenon Medical, Inc. is a listed company in the Healthcare sector, based in Los Gatos, California, USA. Its market value was $6 M on 29 October 2026, which makes it the 26,612th largest listed company in the world and the 4,370th largest in the USA on this site. In the year to December 2025 it had sales of $4 M and a net loss of $13 M. Steven M. Foster is its chief executive. Its shares trade under the symbol TNON (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Tenon Medical, Inc.

TENON MEDICAL, INC. is a medical device company. The headquarters is in United States.

Tenon Medical, Inc. timeline

3 events, 2012–2025
  1. 2012
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2022
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 27 April 2022; shares registered for exchange trading on 26 April 2022.
  5. 2025
  6. 💰
    Record revenue of $4 million
    FY2025, the highest of the 5 years on record.

Events of Tenon Medical, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$5 M$11 M$16 M$22 M2023202420252026

World rank over time

▲ up 2,674 places since 2022
2022-12-25: #29298#29,29820222023-07-30: #32628#32,62820232024-01-05: #32683#32,68320242026-03-08: #12893#12,89320262026-08-01: #23898#23,89820262026-10-13: #27803#27,80320262026-10-29: #26624#26,6242026

Rank in USA: #5,282 (Dec 2022) · #5,575 (Jul 2023) · #4,656 (Jan 2024) · #2,400 (Mar 2026) · #4,158 (Aug 2026) · #4,436 (Oct 2026) · #4,373 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
1.1×
Price / book
1.2×
Free cash flow yield
-181.7%
Net margin (TTM)
-258.0%
Operating margin
-324.6%
Return on equity
-271.8%
Liabilities / assets
53.2%
Revenue growth
+20.1%
R&D / revenue
54.6%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2021: revenue $0M, net income $-7M$0MFY21Fiscal year ending Dec 2022: revenue $1M, net income $-19M$1MFY22Fiscal year ending Dec 2023: revenue $3M, net income $-16M$3MFY23Fiscal year ending Dec 2024: revenue $3M, net income $-14M$3MFY24Fiscal year ending Dec 2025: revenue $4M, net income $-13M$4MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$4M+20.1%$-13M$-13M-318.8%
Dec 2024$3M+11.9%$-14M$-14M-416.8%
Dec 2023$3M+324.6%$-16M$-16M-531.7%
Dec 2022$1M+331.2%$-19M$-19M-2742.0%
Dec 2021$0M—$-6M$-7M-4406.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-11M$0M$-11M$-1.70—
Dec 2024$-10M$0M$-10M$-11.26—
Dec 2023$-12M$0M$-13M$-68.64—
Dec 2022$-12M$1M$-13M$-23.62—
Dec 2021$-4M$0M$-4M$-7.81—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$5M
Net income, trailing 12 months
$-14M
RevenueNet income
Three months to Sep 2024: revenue $1M, net income $-3M$1MSep ’24Three months to Dec 2024 (from the annual report): revenue $1M, net income $-3M$1MDec ’24Three months to Mar 2025: revenue $1M, net income $-4M$1MMar ’25Three months to Jun 2025: revenue $1M, net income $-3M$1MJun ’25Three months to Sep 2025: revenue $1M, net income $-3M$1MSep ’25Three months to Dec 2025 (from the annual report): revenue $1M, net income $-3M$1MDec ’25Three months to Mar 2026: revenue $1M, net income $-3M$1MMar ’26Three months to Jun 2026: revenue $1M, net income $-4M$1MJun ’26

Latest quarter to Jun 2026: revenue $1M (+128.6% on a year earlier), net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Tenon Medical, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$4 M
Operating income
$-13 M
Net income
$-13 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$11 M
Total liabilities
$6 M
Total equity
$5 M

As of December-2025

Top 10 institutional investors in Tenon Medical, Inc.#

As of Sep 30, 2026
10 institutions held 24,539 shares (about 3.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 3.7%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 10 largest institutional investors in Tenon Medical, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Sassicaia Capital Advisers LLC15,000New2.25%$0 MNov 16, 2026
2SBI Securities Co., Ltd.4,484New0.67%$0 MOct 22, 2026
3Vanguard Capital Management LLC2,049New0.31%$0 MNov 13, 2026
4Tower Research Capital LLC (TRC)1,527New0.23%$0 MNov 16, 2026
5Vanguard Fiduciary Trust Co1,275New0.19%$0 MNov 13, 2026
6Robinhood Markets, Inc.128—0.02%$0 MNov 18, 2026
7UBS Group AG68New0.01%$0 MNov 10, 2026
8Morgan Stanley5New0.00%$0 MNov 13, 2026
9Clear Street Group Inc.2New0.00%$0 MNov 16, 2026
10Jpmorgan Chase & Co1New0.00%$0 MNov 12, 2026

Mutual funds holding Tenon Medical, Inc.#

5 funds hold shares worth $0 M (about 32.1% of the company). Since their previous reports 2 added shares and 0 sold, buying $0 M net.
Mutual funds holding Tenon Medical, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC129,687$0 M19.4%<0.01%+166%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.71,715$0 M10.8%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC12,082$0 M1.8%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC638$0 M0.10%<0.01%no changeMay 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC33$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 5 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Tenon Medical, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$500 K
9 purchases, 1 insider
Sold, 12 months
$606 K
9 sales, 1 insider
Net, 12 months
-$105 K
open market only
Insiders on file
13
since
$398 K-$546 K$0Nov 2025: bought $0 (3 trades), sold $0 (0 trades)Nov 25Aug 2026: bought $102 K (2 trades), sold $59 K (4 trades)AugSep 2026: bought $398 K (7 trades), sold $546 K (5 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Tenon Medical, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed HRT Financial LP10% ownerBuy+31,227$2.920$91 K15,839Form 4
filed HRT Financial LP10% ownerBuy+28,267$4.020$114 K15,839Form 4
filed HRT Financial LP10% ownerBuy+8,431$4.920$41 K15,839Form 4
filed HRT Financial LP10% ownerSell-65,582$5.560$365 K15,839Form 4
filed HRT Financial LP10% ownerSell-50,395$2.610$132 K18,182Form 4
filed HRT Financial LP10% ownerBuy+39,508$3.400$134 K18,182Form 4
filed HRT Financial LP10% ownerSell-9,948$4.270$42 K18,182Form 4
filed Kevin WilliamsonChief Financial OfficerShares withheld for tax-11$3.450$382,580Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Tenon Medical, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
94,671
30.5% of shares · 1 days to cover
Reg SHO threshold list
9 days
in the last 90 days
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-09-11 17:46 UTC, code LUDP, resumed 17:51 UTC
  • 2026-09-11 17:32 UTC, code LUDP, resumed 17:42 UTC
  • 2026-09-11 17:22 UTC, code LUDP, resumed 17:32 UTC
  • 2026-09-11 14:55 UTC, code LUDP, resumed 15:00 UTC
  • 2026-09-11 14:47 UTC, code LUDP, resumed 14:52 UTC

Fails to deliver

  • : 10,236 shares at $2.26
  • : 394 shares at $2.14
  • : 282 shares at $2.70
  • : 20 shares at $2.98
  • : 928 shares at $3.44

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Tenon Medical, Inc. scorecard#

Passes 7 of the 17 checks that could be worked out: strongest in growth (3 of 4), weakest in profitability (1 of 5). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.2×Price to book 1.2× against Healthcare's median of 3.1×.
    • ✓Price to sales below its peers' median1.1×Price to sales 1.1× against Healthcare's median of 3.8×.
    • ✗Free cash flow yield above 5%-181.7%Free cash flow is -181.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth3 of 4
    • ✓Revenue grew in the newest year20.1%Revenue up 20.1% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years78.7%78.7% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median78.7%78.7% a year against Healthcare's median of 8.5% (549 companies).
    • ✗Earnings per share grew in the newest year-1.70 vs -11.26Diluted EPS -1.70 in fiscal 2025 against -11.26 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$13 MNet income -$13 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-324.6%-324.6% against Healthcare's median of -7.7% (674 companies).
    • ✗Return on equity above 15%-228.2%-228.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-324.6%-324.6% in fiscal 2025 against -2713.0% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities2.1×Current ratio 2.11 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-13.10Z-score -13.10 (distress zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Tenon Medical, Inc.'s statements, beside the median of Healthcare.

Tenon Medical, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-324.6%-7.7%
Net margin-318.8%-8.1%
Return on equity-228.2%-36.9%
Revenue growth, 3 years a year78.7%8.5%
Revenue growth20.1%10.2%
Free cash flow margin-279.4%-1.3%

5of 8on the Piotroski tests of financial strength

  • Net loss of $13 million, the 5th loss-making year in a row.
  • Free cash flow was negative: -$11 million.
  • Receivables grew 98% while revenue grew 20%: customers are paying later, or sales were booked ahead of cash.
  • Revenue has grown 4 years in a row.

Tenon Medical, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Tenon Medical, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021
Income statement
Revenue3,9443,2772,928691160
Cost of revenue1,5861,5661,6871,33255
Gross profit2,3581,7111,241−641105
Research and development2,1492,6033,1632,8281,718
Selling and marketing6,0265,1096,7787,8332,141
General and administrative6,9757,7657,0277,4232,707
Operating expenses15,15015,47716,96818,0846,566
Operating income−12,792−13,766−15,727−18,725−6,461
Interest expense and finance costs—3421354621
Other non-operating income (expense)23693146−192−620
Income before tax———−18,916−7,079
Net income including minority interests———−18,917−7,081
Minority interests' share of net income———0−33
Net income attributable to shareholders−12,556−13,673−15,581−18,917−7,048
Earnings per share, basic-1.70-11.26-68.64r-23.62r-7.81
Earnings per share, diluted-1.70-11.26-68.64r-23.62r-7.81
Shares, weighted average (basic)0.00.00.0r0.0r0.0
Shares, weighted average (diluted)0.00.00.0r0.0r0.0
Balance sheet
Cash and cash equivalents3,7566,5352,4282,1292,917
Short-term investments———6,4414,404
Receivables1,69886351822876
Inventory1,054606554415188
Other current assets260206389——
Current assets6,7688,2103,8899,3477,672
Property, plant and equipment918752961793101
Right-of-use (leased) assets1313996468731,084
Goodwill2,407————
Other intangible assets485————
Total assets10,7609,8436,34511,0899,272
Accounts payable845369433550478
Current liabilities3,2131,8693,1402,53015,274
Lease liabilities (non-current)—141428683911
Total liabilities5,7203,8725,5674,83716,185
Retained earnings−81,302−68,746−55,073−39,492−20,575
Shareholders' equity5,0405,9717786,252−20,552
Total liabilities and equity10,7609,8436,34511,0899,272
Shares outstanding0.3r3.10.3r1.1r1.0
Cash-flow statement
Depreciation and amortization26240819978—
Share-based compensation1,6913,8454,1452,897377
Cash from operating activities−10,745−9,878−12,183−12,025−4,292
Capital expenditure−273−186−361−847−102
Cash from investing activities−1,023−1866,142−2,884−4,504
Debt issued——495——
Shares issued—2,106495r14,1390
Cash from financing activities8,98914,1256,30214,11411,469
Exchange-rate effect on cash—46387.0−2.0
Change in cash−2,7794,107299−7882,671
Report10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Tenon Medical, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Acquisition or sale completed 1 · Directors and officers 1 · Material agreement 11 · Unregistered share sale 9 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 5

Tenon Medical, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K/A
Results announced8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Material agreement8-K
Directors and officersMaterial agreement8-K
Bylaws or fiscal year changed8-K
Delisting notice8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Delisting notice8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Unregistered share sale8-K
Shareholder vote8-K
Acquisition or sale completedMaterial agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Tenon Medical, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2026$4 MPrivate placement after listing$2 to $10 million1optionsSEC
Aug 2026$3 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Mar 2026$4 MPrivate placement after listing$2 to $10 million6debt, optionsSEC
Nov 2025$3 MPrivate placement after listing$2 to $10 million29equity, optionsSEC
Mar 2025$1 MPrivate placement after listingUnder $2 million1optionsSEC
Mar 2025$5 MPrivate placement after listing$2 to $10 million1optionsSEC
Feb 2024$3 MPrivate placement after listing$2 to $10 million46equity, optionsSEC
Nov 2023$1 MPrivate placement after listingUnder $2 million2debt, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Tenon Medical, Inc. compares in Healthcare

  • Market cap$6 M · higher than 5% of 2,013
  • Revenue$4 M · higher than 17% of 1,795
  • Net margin-258.0% · higher than 9% of 1,485
  • Revenue growth20.1% · higher than 70% of 1,003
  • Price / sales1.1× · lower than 81% of 1,071
  • Price / book1.2× · lower than 78% of 1,245
  • FCF yield-181.7% · higher than 1% of 835
CompanyMarket capP/ENet marginRev. growth
Tenon Medical, Inc.🇺🇸$6 M—-258.0%+20.1%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
UnitedHealth Group Incorporated🇺🇸$367.7 B23.1×3.5%+11.8%
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Tenon Medical, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Tenon Medical, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Tenon Medical, Inc.? Suggest a correction